|
Gefitinib
|
Higashino (7)
|
2010
|
67/F
|
Observation/withdrawal
|
Mild abdominal pain
|
Intra-peritoneal free air
|
Improved
|
ND
|
–
|
|
Gefitinib
|
Iwasaku (8)
|
2012
|
82/F
|
Observation/withdrawal
|
Mild abdominal pain
|
None
|
Improved
|
Yes
|
Yes
|
|
Gefitinib
|
Lee (9)
|
2012
|
66/F
|
Observation/withdrawal
|
Vomiting, diarrhea, and abdominal distension
|
Intra-hepatic portal veinous gas with suggestive of liver infarction
|
Improved
|
No
|
–
|
|
Gefitinib
|
Wakabayashi (10)
|
2012
|
83/M
|
Surgery/ withdrawal
|
Fever, vomiting, diarrhea, and severe abdominal pain
|
Intra-peritoneal free air, remarkable elevation of inflammatory parameters
|
Improved
|
ND
|
–
|
|
Gefitinib
|
Otsubo (11)
|
2015
|
71/M
|
Observation/withdrawal
|
Vomiting, diarrhea, and abdominal pain
|
Intra-peritoneal free air
|
Improved
|
Yes
|
No
|
|
Gefitinib
|
Maeda (12)
|
2016
|
80/F
|
Observation/withdrawal
|
Anorexia, constipation, and abdominal distension
|
Intra-peritoneal free air, mild elevation of inflammatory parameters
|
Improved
|
Yes
|
Yes
|
|
Erlotinib + bevacizumab
|
Tsukita (13)
|
2014
|
69/M
|
Observation/withdrawal
|
No symptoms
|
Intra-peritoneal free air
|
Improved
|
ND
|
–
|
|
Erlotinib + pemetrexed
|
Yamamoto (14)
|
2014
|
70/F
|
Observation, continuation of erlotinib
|
Vomiting, anorexia, diarrhea, and abdominal pain
|
None
|
Improved
|
–
|
–
|
|
Erlotinib + bevacizumab
|
Saito (15)
|
2016
|
73/F
|
Observation/withdrawal
|
Anorexia and fatigue
|
Intra-peritoneal free air
|
Improved
|
No
|
–
|
|
Osimertinib
|
Current case
|
2018
|
73/F
|
Observation/withdrawal
|
No symptoms
|
Intra-hepatic portal vein gas
|
Improved
|
Yes
|
No
|
